miR-26a Limits Muscle Wasting and Cardiac Fibrosis through Exosome-Mediated microRNA Transfer in Chronic Kidney Disease

Abstract

Uremic cardiomyopathy and muscle atrophy are associated with insulin resistance and contribute to chronic kidney disease (CKD)-induced morbidity and mortality. We hypothesized that restoration of miR-26a levels would enhance exosome-mediated microRNA transfer to improve muscle wasting and cardiomyopathy that occur in CKD. Methods: Using next generation sequencing and qPCR, we found that CKD mice had a decreased level of miR-26a in heart and skeletal muscle. We engineered an exosome vector that contained Lamp2b, an exosomal membrane protein gene fused with a muscle-specific surface peptide that targets muscle delivery. We transfected this vector into muscle satellite cells and then transduced these cells with adenovirus that expresses miR-26a to produce exosomes encapsulated miR-26a (Exo/ miR-26a ). Exo/ miR-26a was injected once per week for 8 weeks into the tibialis anterior (TA) muscle of 5/6 nephrectomized CKD mice. Results: Treatment with Exo/ miR-26a resulted in increased expression of miR-26a in skeletal muscle and heart. Overexpression of miR-26a increased the skeletal muscle cross-sectional area, decreased the upregulation of FBXO32/atrogin-1 and TRIM63/MuRF1 and depressed cardiac fibrosis lesions. In the hearts of CKD mice, FoxO1 was activated, and connective tissue growth factor, fibronectin and collagen type I alpha 1 were increased. These responses were blunted by injection of Exo/ miR-26a . Echocardiograms showed that cardiac function was improved in CKD mice treated with Exo/ miR-26a . Conclusion: Overexpression of miR-26a in muscle prevented CKD-induced muscle wasting and attenuated cardiomyopathy via exosome-mediated miR-26a transfer. These results suggest possible therapeutic strategies for using exosome delivery of miR-26a to treat complications of CKD.

Dose-effect relationship and molecular mechanism by which BMSC-derived exosomes promote peripheral nerve regeneration after crush injury

“…At present, intraperitoneal injection, intravenous injection, and local application are the main methods by which EXOs are applied in vivo [ 67 – 69 ]. Muscle injection is primarily used for the treatment and study of skeletal muscle atrophy [ 70 ].…”

Exosome-Mediated siRNA pool Inhibits Axonal Growth Inhibitor in Cortical Neurons of Spinal Cord Injury in Rats

“…Wang has ascertained the treatment for exosomes (containing Lamp2b)/miR-26a elevated cross-sectional areas of skeletal muscles, diminished the upregulation of FOXO32/atrogin-1, and TRIM63/MuRF1 and depressed cardiac brosis lesions. [23] Moreover, exosomes as a kind of extracellular vesicle have emerged as a promising therapeutic delivery platform due to their speci c composition and biological properties, providing the nervous system with effective agents for treating various diseases. [24] A recent study has reported that exosomes from serum-deprived mesenchymal stem cells were utilized to deliver siRNAs to neurons.…”

Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-κB/NLRP3 Pathway

“…Given to these properties, they are recognized as promising biomarkers for diagnosis and prognosis of many diseases ( Gurunathan et al., 2019 ). There is growing evidence that exosomes have therapeutic effects on the renal diseases, such as acute tubular injury ( Pan et al., 2019 ) and chronic kidney disease (CKD) ( Wang B. et al., 2019 ). Furthermore, it has been indicated that exosomes can improve renal ischemic-reperfusion injury (IRI)-induced renal structural injury by restraining nuclear factor-κB (NF-κB) activation to subside the expressions of inflammatory cytokines ( Li L. et al., 2019 ).…”